Your browser doesn't support javascript.
loading
Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database.
Hamano, Hirofumi; Mitsui, Marin; Zamami, Yoshito; Takechi, Kenshi; Nimura, Takahiro; Okada, Naoto; Fukushima, Keijo; Imanishi, Masaki; Chuma, Masayuki; Horinouchi, Yuya; Izawa-Ishizawa, Yuki; Kirino, Yasushi; Nakamura, Toshimi; Teraoka, Kazuhiko; Ikeda, Yasumasa; Fujino, Hiromichi; Yanagawa, Hiroaki; Tamaki, Toshiaki; Ishizawa, Keisuke.
Affiliation
  • Hamano H; Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
  • Mitsui M; Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
  • Zamami Y; Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
  • Takechi K; Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan. zamami@tokushima-u.ac.jp.
  • Nimura T; Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan. zamami@tokushima-u.ac.jp.
  • Okada N; Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.
  • Fukushima K; Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
  • Imanishi M; Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
  • Chuma M; Department of Molecular Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
  • Horinouchi Y; Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
  • Izawa-Ishizawa Y; Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.
  • Kirino Y; Department of Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
  • Nakamura T; Department of Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
  • Teraoka K; Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
  • Ikeda Y; Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
  • Fujino H; Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
  • Yanagawa H; Department of Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
  • Tamaki T; Department of Molecular Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
  • Ishizawa K; Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.
Support Care Cancer ; 27(3): 849-856, 2019 Mar.
Article in En | MEDLINE | ID: mdl-30062585
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Topoisomerase I Inhibitors / Irinotecan / Neutropenia Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Support Care Cancer Journal subject: NEOPLASIAS / SERVICOS DE SAUDE Year: 2019 Type: Article Affiliation country: Japan
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Topoisomerase I Inhibitors / Irinotecan / Neutropenia Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Support Care Cancer Journal subject: NEOPLASIAS / SERVICOS DE SAUDE Year: 2019 Type: Article Affiliation country: Japan